pubmed.ncbi.nlm.nih.gov

Comparative frequency of specified adverse events following Vero cell culture-derived Japanese encephalitis and Vi capsular polysaccharide typhoid vaccines in U.S. military personnel, July 2011-August 2019 - PubMed

  • ️Sun Jan 01 2023

Comparative frequency of specified adverse events following Vero cell culture-derived Japanese encephalitis and Vi capsular polysaccharide typhoid vaccines in U.S. military personnel, July 2011-August 2019

Srihari Seshadri et al. Vaccine. 2023.

Abstract

Vero cell culture-derived Japanese encephalitis (JE) vaccine (JE-VC; Ixiaro) was approved in the United States in 2009. The previous JE vaccine, an inactivated mouse brain-derived vaccine, had been associated with rare, but serious, allergic and neurologic adverse events (AE). Studies and AE surveillance have supported JE-VC's safety, but one evaluation among military personnel found elevated hypersensitivity and neurologic AE rates. However, co-administration of multiple vaccines to some personnel might have affected results. We retrospectively compared rates of hypersensitivity and neurologic AEs within 28 days following vaccination of military personnel with JE-VC or parenteral Vi capsular polysaccharide typhoid vaccine administered without other vaccines from July 1, 2011, through August 31, 2019. Rates of most events were similar between the vaccines. Only delayed hypersensitivity reactions occurred more frequently following JE-VC (rate ratio: 4.2, 95 % CI 1.2-15.3; p = 0.03), but rates were low for both vaccines. These results support JE-VC's safety.

Keywords: Adverse event; Convulsions; Delayed Hypersensitivity; Japanese encephalitis; Japanese encephalitis vaccine; Retrospective; Typhoid vaccine; Vaccine safety; Vero cell-derived.

Published by Elsevier Ltd.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Similar articles

References

    1. Campbell GL, Hills SL, Fischer M, Jacobson JA, Hoke CH, Hombach JM, et al. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ 2011;89(766-74):74A–A. - PMC - PubMed
    1. Hills SL, Walter EB, Atmar RL, Fischer M, Group AJEVW. Japanese Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2019;68:1–33. - PMC - PubMed
    1. Lindsey NP, Staples JE, Jones JF, Sejvar JJ, Griggs A, Iskander J, et al. Adverse event reports following Japanese encephalitis vaccination in the United States, 1999–2009. Vaccine 2010;29:58–64. - PubMed
    1. Food and Drug Administration. Ixiaro. March 30, 2009. Approval Letter. Available at: https://www.fda.gov/vaccines-blood-biologics/vaccines/ixiaro.
    1. VLA-401: JE-VC post-marketing adverse event surveillance among U.S. military personnel. Presentation to: Advisory Committee on Immunization Practices. 2017.

MeSH terms

Substances